Skip to main content

Table 1 Clinical characteristics of all participants.

From: TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes

  Treatment with sulfonylurea (A1C <7%) Failure of treatment with sulfonylurea (A1C≥7%) P-value
  N = 92 N = 97  
Gender (Male/Female) 45/47 47/50 0.95*
Age (yr) 78.2 ± 9.6 78.3 ± 9.0 0.98
BMI (kg/m2) 26.8 ± 5.2 27.0 ± 4.7 0.71
Creatinine (mg/dl) 1.73 ± 1.20 1.52 ± 0.55 0.13
Creatinine clearence (ml/min) 42.96 ± 22.61 42.10 ± 18.77 0.79
A1C (%) 6.13 ± 0.51 7.65 ± 1.40 <0.001
Age at onset of diabetes (yr) 68.0 ± 13.4 66.0 ± 10.9 0.28
Diabetes duration (yr) 10.2 ± 9.5 11.9 ± 8.4 0.20
Co-medication (n all drugs) 7 ± 3 7 ± 3 0.29
Sulfonylurea daily dose (mg) 3.68 ± 6.40 4.24 ± 6.85 0.56
Metformin treatment (n patients) 32 40 0.36*
  1. Data are mean ± SD; P- values for comparisons between genotypic groups by ANOVA statistics;
  2. *- χ2 test.